Patent intelligence · CA
CA 2673419
COMPOSITION PHARMACEUTIQUE
COMPOSITION PHARMACEUTIQUE
Patent details — CA 2673419
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Jun 26, 2008
- Expiration
- Jun 21, 2028
- Applicant
- GENERICS UK LTD [GB]
- CPC classes
- A61K 9/ 14 A I, A61K 31/ 569 A I, A61K/31569, A61K/91623
Quick answer
CA 2673419 (COMPOSITION PHARMACEUTIQUE) is held by GENERICS UK LTD [GB]. Status: granted. Granted Jun 26, 2008. Expires Jun 21, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GENERICS UK LTD [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 14 A I, A61K 31/ 569 A I, A61K/31569, A61K/91623, A61K/91652, A61K/92018
More from GENERICS UK LTD [GB]
Related pharmaceutical patents in our USPTO index.
-
CA 2767560
ATOVAQUONE A DIAMETRE DE PARTICULES (D<SB>90</SB>) VARIANT DE PLUS DE 3UM A ENVIRON 10UM
granted -
CA 2765866
FORMULATION PHARMACEUTIQUE
granted -
CA 2712282
COMPOSITION PHARMACEUTIQUE DE DULOXETINE A LIBERATION RETARDEE
granted -
CA 2702664
FORMULATION PHARMACEUTIQUE A LIBERATION CONTROLEE
granted -
WO 2009026621
COMPOSÉ ET COMPOSITION PHARMACEUTIQUES
granted -
CA 2677623
FORME PHARMACEUTIQUE CONTENANT DEUX OU DAVANTAGE DE PRINCIPES ACTIFS PHARMACEUTIQUES SOUS DES FORMES PHYSIQUES DIFFERENTES
granted -
CA 2673418
COMPOSE ET COMPOSITION PHARMACEUTIQUES
granted
Frequently asked questions
What is US patent 2673419?
CA 2673419 (COMPOSITION PHARMACEUTIQUE) is held by GENERICS UK LTD [GB]. Status: granted. Granted Jun 26, 2008. Expires Jun 21, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2673419?
GENERICS UK LTD [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does CA 2673419 expire?
Our index shows an expiration date of Jun 21, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.